News
After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis
After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema
